Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry
Authors:
- John J. MilesJMJohn J. Miles
- Mai Ping TanMTMai Ping Tan
- Garry DoltonGDGarry Dolton
- Emily S.J. EdwardsEmily S.J. Edwards
- Sarah A.E. GallowaySGSarah A.E. Galloway
- Bruno LaugelBLBruno Laugel
- Mathew ClementMCMathew Clement
- Julia MakindeJMJulia Makinde
- Kristin LadellKLKristin Ladell
- Katherine K. MatthewsKMKatherine K. Matthews
- Thomas S. WatkinsTWThomas S. Watkins
- Katie TungattKTKatie Tungatt
Open Access
- 12 March 2018
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (4) , 1569-1580
Abstract
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.Keywords
Funding Information
- BBSRC (BB/H001085/1)
- Cardiff Synthetic Biology Initiative (Seedcorn)
- Perpetual Research Grant (FR2013/0946)
- Medical Research Council (UK) (Studentship)
- Health and Care Research Wales (Translational Fellowship to Man Ping Tan)
- Australian Research Council Future Fellowship (FT100100476)
- Australian Research Council Future Fellowship (FF120100416)
- Australian National Health and Medical Research Council (Fellowships)
- Wellcome Trust (Senior Investigator Awards)
This publication has 59 references indexed in Scilit:
- Why must T cells be cross-reactive?Nature Reviews Immunology, 2012
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- Tricks with tetramers: how to get the most from multimeric peptide–MHCImmunology, 2009
- More than one reason to rethink the use of peptides in vaccine designNature Reviews Drug Discovery, 2007
- T Cell Determinants Incorporating β-Amino Acid Residues Are Protease Resistant and Remain Immunogenic In VivoThe Journal of Immunology, 2005
- Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative ColitisInflammatory Bowel Diseases, 2005
- H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategiesEuropean Journal of Immunology, 1999
- D-peptides as immunogens and diagnostic reagentsCurrent Opinion in Biotechnology, 1998
- Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment.Journal of Experimental Medicine, 1995
- Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytesEuropean Journal of Immunology, 1993